All Stories

Rivus’ weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

Rivus’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the drug's obesity potential.

Jun 24, 2025 - 16:25
 0
Rivus’ weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential
Rivus’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the drug's obesity potential.
Read More

Tags:

Previous Article

Regulatory tracker: FDA clears GSK’s Benlysta autoinjector in kids with lupus ne...

Next Article

MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b

Related Posts

Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock soaring

Exelixis' blockbuster hopeful beats Bayer drug in pivot...

Jun 23, 2025  0

Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2

Atsena eye disease gene therapy hits safety goals, clos...

May 19, 2025  0

RA Capitals biotech incubator lays off staffers: Stat

RA Capitals biotech incubator lays off staffers: Stat

May 14, 2025  0